benign cephalic histiocytosis
MONDO:0015533
Research intelligence
Directly mapped studies only · unique clinical trialsCurrent registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.
Medications under investigation
Verified disease and drug mappings that co-occur within the same study; not evidence of effectiveness.
MONDO disease family
Recruiting studies by city
Trial status
Trial phase
Study start year
Investigated drug interventions
Benign cephalic histiocytosis
Benign cephalic histiocytosis (BCH) is a non-Langerhan's histiocytosis that is uncommon and self-limiting, usually beginning towards the end of the first year of life. Gianotti et al. originally described it in 1971. Initially affecting the head and neck, this condition is characterized by several small eruptions of yellow to reddish-brown papules that heal on their own. Histological investigations have demonstrated that this disorder is associated with dermal proliferation of histiocytes, characterized by intracytoplasmic comma-shaped bodies, covered vesicles, and desmosome-like structure.
Background only. Canonical identity remains MONDO; clinical-trial relationships come from ClinicalTrials.gov.Drugs being studied
Disease identity and terminology: MONDO. Trial relationships: ClinicalTrials.gov.